**Epidemics of chikungunya, Zika, and COVID-19 reveal bias in case-based mapping**

Fausto Andres Bustos Carrillo (ORCID: 0000-0002-7263-5625)[1]; Brenda Lopez Mercado[2]; Jairo Carey Monterrey[2]; Damaris Collado[2]; Saira Saborio[2]; Tatiana Miranda[2]; Carlos Barilla[2]; Sergio Ojeda[2]; Nery Sanchez[2]; Miguel Plazaola[2]; Harold Suazo Laguna[2]; Douglas Elizondo[2]; Sonia Arguello[2]; Anna M. Gajewski[2]; Hannah E. Maier[3]; Krista Latta[3]; Bradley Carlson[3]; Josefina Coloma[1]; Leah Katzelnick[1]; Hugh Sturrock[4,5]; Angel Balmaseda[2,6]; Guillermina Kuan[2,6]; Aubree Gordon (ORCID: 0000-0002-9352-7877)[3#*]; Eva Harris (ORCID: 0000-0002-7238-4037)[1#*]

**Author affiliations:**

[1] University of California, Berkeley, Berkeley, California, USA

[2] Sustainable Sciences Institute, Managua, Nicaragua

[3] University of Michigan, Ann Arbor, Michigan, USA

[4] University of California, San Francisco, San Francisco, California, USA

[5] Locational, Poole, UK

[6] Ministry of Health, Managua, Nicaragua

# These senior authors contributed equally to this article

**\*Co-corresponding authors:**

Eva Harris, Division of Infectious Diseases and Vaccinology, School of Public Health, University of California, Berkeley, 185 Li Ka Shing Center, 1951 Oxford Street, Berkeley, CA 94720-3370; Tel. 1-510-642-4845; eharris@berkeley.edu

Aubree Gordon, Department of Epidemiology, School of Public Health, University of Michigan,

Ann Arbor, 5622 SPH I, 1415 Washington Heights, Ann Arbor, MI 48109-2029; Tel. 1-510-409-

5495; gordonal@umich.edu

Main text: 3500 / 3500, Abstract: 150 / 150

Keywords: Chikungunya, Zika, COVID-19, bias, spatial analysis, epidemiology

Running title: Four epidemics reveal bias in case-based mapping

Article summary line: Inferring measures of spatial risk from case-only data can substantially

bias estimates, thereby weakening and potentially misdirecting measures needed to control an

epidemic.

**ABSTRACT**

Accurate tracing of epidemic spread over space enables effective control measures. We examined three metrics of infection and disease in a pediatric cohort (N≈3,000) over two chikungunya and one Zika epidemic, and in a household cohort (N=1,793) over one COVID-19 epidemic in Managua, Nicaragua. We compared spatial incidence rates (cases/total population), infection risks (infections/total population), and disease risks (cases/infected population). We used generalized additive and mixed-effects models, Kulldorf's spatial scan statistic, and intracluster correlation coefficients. Across different analyses and all epidemics, incidence rates considerably underestimated infection and disease risks, producing large and spatially non-uniform biases distinct from biases due to incomplete case ascertainment. Infection and disease risks exhibited distinct spatial patterns, and incidence clusters inconsistently identified areas of either risk. While incidence rates are commonly used to infer infection and disease risk in a population, we find that this can induce substantial biases and adversely impact policies to control epidemics.

## INTRODUCTION

Controlling epidemic spread requires accurate data on the movement of pathogens through populations. Standard spatial studies of infectious diseases use passively collected, individual-level data for cases (symptomatic infections) from health facilities after cases present for medical treatment (1–5). Then, by using census data to obtain the total population in an area, these studies estimate incidence rates (attack rates, incidence proportions) as the ratio of cases to the total population. However, because this approach does not capture subclinical (clinically inapparent) infections, this incidence approach may not recapitulate the spatial contour of infections, which may have a distinct pattern and magnitude. These issues may be compounded when the incidence rate, estimated from passively collected and hence incomplete case data, is used to infer infection risk (1–3) or disease risk (4,5) in policy decision-making on epidemic control.

Epidemiological risk is the probability of a susceptible individual experiencing an outcome. For an immunologically naïve population, all persons are at risk for an initial infection. However, only infected individuals are at risk for experiencing illness, as only infected persons are susceptible to disease. Consequently, measuring infection status is necessary to estimate the numerator of infection risk (infections/total population) and the denominator of disease risk (cases/infected population). These metrics are related to the incidence rate through an application of conditional probability, expressed in multiple ways below:

Epidemiological:         Infection risk × Disease risk = Incidence rate (Eq. 1)

Algebraic:         $\dfrac{\text{Infections}}{\text{Total population}} \times \dfrac{\text{Cases}}{\text{Infections}} = \dfrac{\text{Cases}}{\text{Total population}}$

Statistical:         P(Infection) × P(Disease | Infection) = P(Disease and Infection)

Eq. 1, applicable to infectious disease epidemics in an initially naïve population, demonstrates

that incidence is the product of two underlying probabilities of interest. Thus, the incidence rate

is explained by, and can be decoupled into, infection and disease risks.

We spatially analyzed four explosive epidemics in two longitudinal Nicaraguan cohorts.

Our analysis covers the 2014 and 2015 chikungunya epidemics caused by chikungunya virus

(CHIKV) (6,7), the 2016 Zika epidemic caused by Zika virus (ZIKV) (8,9), and the first wave of

the COVID-19 epidemic in 2020 caused by severe acute respiratory syndrome coronavirus 2

(SARS-CoV-2) (10). While *Aedes* mosquitoes transmit CHIKV and ZIKV (11), SARS-CoV-2

primarily spreads by respiratory droplets (12). We analyzed the epidemics in parallel to identify

commonalities across epidemics of different pathogens and transmission routes. We

demonstrated differences in the fine-scale spatial characterization of epidemics by standard

incidence-based measures versus a more comprehensive approach that included infection and

disease risks. Finally, we quantified and mapped the separate biases induced by using passive

versus active surveillance.

**METHODS**

**Ethics statement**

The Pediatric Dengue Cohort Study (PDCS) was approved by Institutional Review

Boards (IRBs) of the University of California, Berkeley; the University of Michigan, Ann Arbor;

and the Nicaraguan Ministry of Health. The Household Influenza Cohort Study (HICS) was

approved by the University of Michigan, Ann Arbor, and the Nicaraguan Ministry of Health

IRBs. Participants' parents or legal guardians provided written informed consent. Subjects six

years and older provided verbal assent.

**Study design and eligibility criteria**

The PDCS (13) is an open, population-based, prospective cohort of children initiated in 2004 to study dengue virus and later expanded to include CHIKV and ZIKV. We assessed ~3,000 PDCS participants 2-14 years old who experienced two chikungunya epidemics and one Zika epidemic (6–9). The HICS is an open, population-based, prospective cohort of households that has studied influenza virus and coronaviruses since 2017. We evaluated 1,793 HICS participants 0-87 years old who experienced the first COVID-19 epidemic (10). The age structure of the HICS is representative of Managua's general population.

Both cohort studies share the same study site (Fig. 1) in Managua, Nicaragua's capital. During the studies' annual sampling (serosurvey) in March/April, participants provide blood samples to ascertain infection status during the prior year. A mid-year sampling was instituted in the HICS in October/November 2020 to measure SARS-CoV-2 infections after the first COVID-19 wave but before the second. Both studies provide participants with primary care; participants agree to visit the study health center at the first indication of any illness.

Analysis of each epidemic was restricted to participants who lived within the health center's catchment area and were immunologically naïve. By further restricting to participants who were enrolled before each epidemic, we analyzed a closed cohort of initially uninfected participants who subsequently experienced an epidemic. The Appendix (pages 1-3) contains additional study design information.

**Laboratory methods**

Upon collection, annual blood samples were immediately transported to the Nicaraguan National Virology Laboratory for processing and storage at -80°C. Paired annual samples (2014-2015 and 2015-2016) demonstrating seroconversion by CHIKV Inhibition ELISA (14) indicated

CHIKV infection. ZIKV infection status was confirmed by the 2017 result of the ZIKV NS1

blockade-of-binding assay (15) on paired 2017-2018 annual samples. SARS-CoV-2 infection

status was confirmed by the "Mount Sinai ELISA" protocol (16), primarily on 2020 midyear

samples. Participants with laboratory-confirmed infections who did not seek medical care were

categorized as experiencing subclinical infections. Acute and convalescent samples from

participants suspected of chikungunya, Zika, or COVID-19 were tested using molecular,

virological, and serological assays (7,8,13). The Appendix (pages 3-4) contains detailed

laboratory methods.

**Statistical analyses**

We measured the incidence rate, infection risk, and disease risk of each epidemic. Overall

values of these metrics were estimated using intercept-only logistic models. The metrics' values

across the study area were estimated with generalized additive models (17) using two-

dimensional splines on households' longitude and latitude, where participants were geolocated.

To quantify bias arising from incomplete case ascertainment, Zika case data was disaggregated

by whether they were obtainable through active or passive surveillance, the only epidemic where

this was possible. The intracluster correlation coefficient was used to measure the intra-

household correlation of infection and disease outcomes. We used SaTScan v9.4.4 and

Kulldorf's spatial scan statistic to identify hierarchical and Gini clusters of case incidence,

infection risk, and disease risk (18,19). Geostatistical mixed models (20) were used to describe

the association of risk factors with infection and disease outcomes. Infection dynamics were

estimated by treating cases as a spatiotemporal Poisson point process arising from the total

population and then accounting for the spatial distribution of disease risk, assumed to be time-

invariant. Initially uninfected participants were considered at risk for infection; infected

participants were considered at risk for disease. Analyses used the EPSG:4326 coordinate

reference system and were performed in R v3.6.2. The Appendix (pages 5-15) contains detailed

statistical methods.

**RESULTS**

**Participant characteristics**

We refer to the first chikungunya epidemic as *ChikE1*, the second as *ChikE2*, the Zika

epidemic as *ZikaE,* and the COVID-19 epidemic as *CovidE*. Our study assessed infection and

disease outcomes for 4,884 distinct individuals, including 3,693 unique PDCS participants across

ChikE1, ChikE2, and ZikaE. Of the 1,793 HICS participants, 602 children were also enrolled in

the PDCS, and 1,192 mostly adult participants were only enrolled in the HICS. Approximately

3,000 PDCS participants were analyzed in ChikE1, ChikE2, and ZikaE (Table 1). These three

epidemics occurred in 2014-2016 throughout Managua's rainy period of June-November (Fig.

2), during which an abundance of mosquitoes is observed in the study area. In contrast, CovidE

peaked during May-July of 2020.

In the PDCS, the distribution of age and sex was constant across ChikE1, ChikE2, and

ZikaE (Table S1, Fig. S1), with approximately 50% of PDCS participants being female. In the

HICS, there was an over-enrollment of adult females relative to adult males.

**Summary measures of infection, disease, and case-based incidence**

We first examined summary statistics of the four epidemics. ChikE1 exhibited the lowest

incidence at 2.9 cases per 100 population (2.9%) but featured higher infection (6.4%) and disease

risks (45.6%) (Table 1). ChikE2, ZikaE, and CovidE exhibited similar incidence rates between

14.5-17.1%, but these incidence rates differed substantially from infection and disease risks.

ChikE2 had a medium level of infection risk (24.8%) and a high disease risk (58.7%), an

inverted pattern from what was observed during CovidE, with high infection risk (57.5%) and

medium disease risk (28.9%) (Table 1). In contrast, ZikeE displayed intermediate levels of

infection (47.1%) and disease (35.4%) risk. Across epidemics, the case-based incidence rate thus

recapitulated neither risk-based metric and often underestimated them considerably (Table 1).

We then assessed summary statistics by sex and age. Sex-based differences for incidence

and risk-based measures, even when statistically significant, tended to be small, as when females

had an infection risk 6% higher than males during ZikaE (Fig. S2). Similarly, accounting for the

over-enrollment of adult females in the HICS had little effect (~1%) on overall estimates (Fig.

S3-S4). In contrast, we observed age-based incidence patterns for all epidemics (Fig S5), which

were explained by the underlying and more striking age trends observed for infection and/or

disease risks (Fig S6-8). For example, COVID-19 incidence was low across age, particularly

during childhood (Fig. S5). However, SARS-CoV-2 infection risk was high across all ages,

increasing modestly from ~48% in infants to ~62% at age 24 and thereafter plateauing. Despite

the relative stability of infection risk by age, disease risk during CovidE increased dramatically

from ~11% in infants to ~50% at age 70. Thus, the low COVID-19 incidence neither

recapitulated age-based risk dynamics nor reflected the greater age-based changes in disease risk

as compared to infection risk.

**Mapping infection, disease, and incidence**

Next, we mapped the infection risk, disease risk, and case-only incidence rate across our

study area. For all epidemics, infection risk varied at small spatial scales (Fig. 3A-D), suggesting

that the local environment was an important determinant of infection risk. During ChikE1,

ChikE2, and ZikaE, infection risk was elevated in western neighborhoods adjacent to a large

cemetery that is heavily infested with *Aedes* mosquitoes during the rainy season (data not

shown). Only adjusting Fig. 3A-D for distance to the cemetery appreciably changed the spatial

patterns of infection risk, whereas adjusting for age, sex, and household water availability did not

(Figs. S9-S14). Conversely, SARS-CoV-2 infection risk was high in eastern neighborhoods that

contain large public spaces and commercial attractions (Figs. 3D, S15-S16). Together, these

observations imply that infection risk across epidemics was spatially mediated by distinct

transmission routes.

Across all epidemics, disease risk also varied at small spatial scales (Fig. 3E-H). After

adjusting for age and sex (Figs S17-24), spatial patterns of disease risk remained non-uniform

and distinct from spatial patterns of infection risk. This demonstrates that disease risk can vary

spatially and that areas of high infection risk may not have commensurate levels of disease risk.

As the case-based incidence rate is the product of two risks (Eq. 1) with different spatial

patterns (Fig. 3A-H), maps of the incidence rate (Fig. 3I-L) underestimated infection and disease

risk-based maps and did not recapitulate spatial patterns of either risk. We quantified the bias

resulting from treating the incidence rate as infection and disease risk by subtracting incidence

maps from risk-based maps (Fig. 3M-T). The average spatial bias for the disease risk was -40.1

and -41.2 percentage points for ChikE1 and ChikE2, respectively; the average spatial bias for the

infection risk was -34.9 and -40.3 percentage points for ZikaE and CovidE, respectively. The

incidence rate underestimates risk-based metrics, inducing negative biases. Additionally, bias

varied substantially across neighborhoods. For example, the *range* of bias for ChikE2 and

CovidE infection risks was 31.2 and 19.2 percentage points across the study area. Thus, the

inferential bias induced by treating the incidence rate as a risk-based metric was high and

spatially heterogeneous across epidemics.

**Cluster detection**

We then identified hierarchical and Gini clusters of infection risk, disease risk, and

incidence (Fig. 4, Table S2). Each epidemic had ≥1 significant infection or disease cluster.

Clusters of elevated infection risk for the larger mosquito-borne epidemics, ChikE2 and ZikaE,

encompassed the cemetery and study neighborhoods adjacent to it. Large clusters of diminished

infection risk in ChikE1, ChikE2, and ZikaE highlighted areas with excess uninfected persons

who remained susceptible to future infection. Such clusters are only identifiable after

ascertaining the infection status of a population, regardless of disease presentation. In contrast to

the mosquito-borne epidemics, CovidE exhibited small clusters of elevated and diminished

infection risk. In general, clusters of infection risk were in different locations and of different

sizes than clusters of disease risk, demonstrating that infection and disease risk cluster differently

in space. Indeed, we detected no disease risk clusters during both chikungunya epidemics despite

finding large clusters of infection risk.

Standard incidence clusters, which identify areas of elevated or diminished case counts

among the total population, sometimes missed large risk-based clusters (Fig. 4). More

surprisingly, incidence clusters resembled infection risk clusters only for ChikE2 and CovidE,

whereas they resembled disease risk clusters for ChikE1 and ZikaE. Thus, incidence clusters

failed to display a reproducible pattern, inconsistently resembling either infection or disease risk

clusters for a given epidemic.

**Geostatistical modeling**

We next conducted geostatistical multivariable modeling. We first describe model-based

inferences for correlated outcomes within households and across space. Surprisingly, analyses

that did and did not account for household-based correlation yielded very similar results for all

epidemics, suggesting that participants' infection and disease outcomes were poorly correlated

within homes (Tables S3-S4). This observation was directly confirmed by low values of the

intracluster correlation coefficient (Tables 1, S5). We further observed that infection risk did not

scale with household size (Fig. S25). Altogether, the data demonstrated that our participants'

infection and disease outcomes were weakly correlated within households across epidemics.

Likewise, the similarity of estimates from models that did and did not account for spatial

autocorrelation (Tables S3-S4) suggested that infection and disease outcomes were only spatially

correlated across short distances. This observation was confirmed by estimated Matérn

correlation functions (Fig. S26) that demonstrated that infection and disease outcomes were

spatially correlated across short distances (<200m) for all epidemics, strengthening earlier

findings (Fig. 3) regarding the importance of the local spatial environment.

Indeed, we observed that distance to the cemetery was significantly associated with

ZIKV *infection*, such that the odds of ZIKV infection among participants living 1 km from the

cemetery were 0.63 (95% CI: 0.55, 0.73) times that of participants living next to the cemetery,

conditional on age, sex, and indoor water availability; a similar 1-km odds ratio was observed

during ChikE2 (Table S3). However, using geostatistical models, we did not identify variables

that were consistently related to *disease* risk across epidemics (Table S4). Rather, model results

were epidemic-specific.

**Spatiotemporal dynamics**

Spatiotemporal analyses depict epidemic progression across time and space. By

harnessing Eq. 1, we estimated the spatiotemporal dynamics of infection risk (Fig. 5A-D), which

were substantially underestimated by the less dynamic standard spatiotemporal patterns of case

incidence (Fig. 5E-H). Each of the mosquito-borne epidemics featured elevated infection risk

around cemetery-adjacent neighborhoods for ≥2 months, with particularly high infection risk

during ZikaE. In contrast, cemetery-adjacent neighborhoods were never the focal point of SARS-

CoV-2 infection risk. Because CovidE featured the lowest disease risk (Table 1), its

spatiotemporal *infection* dynamics differed most from its *incidence* dynamics, underscoring the

substantial differences of risk-based mapping compared to case-based mapping.

**Active versus passive surveillance**

We quantified case ascertainment bias spatially by complementing the ZikaE serosurvey

with either all Zika cases or only cases captured by passive surveillance. Compared to our active

surveillance, using passive surveillance altered the clinical profile of captured Zika cases (8) and

decreased the case count, thereby increasing the number of subclinical ZIKV infections. The

infection risk was unbiased under passive surveillance as its calculation only required serosurvey

data; however, estimates of the disease risk and incidence rate were biased (Table 2). The bias

from passive surveillance is conceptually and numerically distinct from that induced by treating

the incidence rate as a risk. However, these two biases synergized when the incidence rate,

estimated from passive surveillance data, was interpreted as a risk. For example, inferring the

true disease risk from the incidence rate induced -4.9 percentage points of bias from incorrect

inference *and* -26.1 percentage points of bias from incomplete case ascertainment (Table 2).

Importantly, this compounded bias would be present irrespective of conducting a serosurvey

(Table 2). Moreover, whether biases arose from misinterpretation, incomplete case data, or both,

they tended to be high and spatially heterogenous (Figure 6). Thus, inferring risk from passive

surveillance data was prone to multiple biases with different spatial patterns.

**DISCUSSION**

Across multiple analyses and four epidemics of three viruses in two cohorts, we showed that the traditional case-based incidence rate considerably underestimated infection and disease risks, broadly impacting how epidemics were characterized. We further demonstrated that case-based analyses did not recover either the magnitude or spatial pattern of infection risk, which critically conveys the landscape of natural immunity. In general, we observed that case-based incidence had more limitations than traditionally assumed. For example, although ChikE2, ZikaE, and CovidE had comparable incidence rates, their underlying infection and disease risks were very different. Similarly, case-based incidence clusters inconsistently captured different risks across epidemics, an observation not apparent without analyzing multiple epidemics in parallel. Together, our results demonstrate how complex, epidemic-specific spatial patterns of infection and disease risk, critical for the design of effective interventions, can be obscured and underestimated by relying solely on case-based analyses. Importantly, this underestimation was distinct from bias due to incomplete case ascertainment, suggesting that the inferential biases we quantify for the incidence rate are exacerbated in typical settings with limited active surveillance and laboratory testing capacity.

Paradoxically, the limitations of the incidence rate are obvious yet underappreciated. It is well-known that incidence estimates based on incomplete case data are underestimated. Here, we showed that a separate bias, with its own spatial pattern, arises when the incidence rate is misinterpreted as conveying infection or disease risks, and we quantified the extent to which this biased estimate deviates from more accurate estimates of infection and disease risk. Correctly interpreting measures of epidemic impact is important for policy decisions. While interventions will vary depending on the pathogen and available countermeasures, areas prone to high

*infection* risk generally require interventions that limit transmission (*e.g.*, mosquito control,

masking, and social distancing), whereas areas prone to high *disease* risk require interventions

that limit disease occurrence and boost access to care.

Incidentally, if the disease risk were spatially uniform, as some studies have assumed

(21), then the spatial pattern of incidence would equal that of the infection risk and the degree of

underestimation (and hence bias) would be similar across a given area. However, disease risk

was not spatially uniform across epidemics, and its bias also varied spatially. Thus, just as others

have found that disease risk can vary across populations (6,22), we find that disease risk can vary

within a single population.

The case-based incidence rate is the disease risk when all individuals are susceptible to an

outcome (*e.g.*, cardiovascular disease, death). However, for pathogens that cause subclinical

infections, incidence rate maps only convey *where disease occurred*, not the *spatial risk* of

infection or disease. Many pathogens of global health importance give rise to substantial

quantities of subclinical infections (including *Plasmodium*; *Mycobacterium tuberculosis*; and

many pathogens transmitted by sex, air, vectors, and soil). Thus, our findings concerning the

limitations of case-based spatial mapping likely generalize to many infectious diseases that

disproportionately affect neglected populations.

The pediatric nature of the PDCS precluded spatially analyzing adults in the catchment

area of the study health center during ChikE1, ChikE2, and ZikaE. However, previous analyses

compared ZIKV infection risk for children and adults in this area (9). The two groups' spatial

patterns were comparable, although ZIKV infection risk was higher among adults. Thus,

analyses of the adult population during ChikE1, ChikE2, and ZikaE would likely reveal similar

spatial trends as those in PDCS participants.

We found little evidence that infections were clustered within households. Lacking

entomological data, our analyses indirectly suggested that viral transmission infrequently

occurred within study households. However, this suggestion is directly supported by a study of

full-length sequencing of ZIKV genomes in our cohort (23), which found that many households

had Zika cases whose most recently sampled viral ancestral strains derived from different

households. Together, the evidence suggests that non-household transmission played an

important role in the epidemics we assessed.

The geographic extent of our study is small. However, capturing all infections and cases,

and hence accurately measuring bias, is only cost-feasible in constrained geographical areas.

Spatial studies with incomplete infection and case data, whether small or large, may be subject to

inferential and case ascertainment biases despite being unable to measure such biases.

Ascertaining infection status and exhancing case surveillance, where possible, may help to

mitigate and correct for such biases.

Measuring a population's infection status has many additional benefits, especially in

directing infection control interventions to areas of high transmission. Conversely, knowledge of

areas with a high proportion of uninfected individuals is also critical for advancing public health

goals, such as prioritizing these areas for epidemic-preventive measures (*e.g.*, vaccine rollout in

areas with low SARS-CoV-2 transmission). Others have shown how combining regional

serosurvey data with real-time hospitalization data can estimate infection risk in near real-time at

larger spatial scales, thereby improving critical estimates for decision-makers (24). As epidemic

management necessitates evaluating the risks of infection and disease across space, our data

supports the expanded use of serosurveys to overcome the inherit limitations of case-based

spatial measures.

**ACKNOWLEDGMENTS**

We are extremely appreciative of our dedicated study team at the Centro de Salud Sócrates

Flores Vivas and the Laboratorio Nacional de Virología at the Centro Nacional de Diagnóstico y

Referencia, Nicaraguan Ministry of Health; and the Sustainable Sciences Institute in Nicaragua.

We are grateful to Art Reingold and Tulika Singh for their thoughtful reviews of the manuscript,

and we thank Burke Bundy and Suzanne Default at the University of California, Berkeley, for

enabling us to use the computer cluster of the Division of Epidemiology and Biostatistics for our

geostatistical modeling. We thank François Rousset for expert consultation regarding spatial

generalized linear mixed models and their implementation in the spaMM R package. Most

importantly, we thank the PDCS and HICS study participants and their families for engaging

with us in the endeavor of science. This study was supported by grants R01 AI099631 (AB), P01

AI106695 (EH), R01 AI120997 (AG), and U19 AI118610 (EH) from the National Institute of

Allergy and Infectious Diseases of the National Institutes of Health; the National Institutes of

Health Centers of Excellence for Influenza Research and Surveillance [contract: HHS

272201400006C (AG)]; and the Open Philanthropy Project Fund for the production of

recombinant SARS-CoV-2 spike protein, its receptor binding domain, and antibodies at the

University of Michigan Center for Structural Biology. FBC was partially supported by a

supplement to grant P01 AI106695.

**ABOUT THE AUTHOR**

Dr. Fausto Andres Bustos Carrillo is an epidemiologist in Washington, DC, collaborating with

the National Institute of Allergy and Infectious Diseases as an Emerging Leader in Data Science

Fellow. His primary research interests are the epidemiological, clinical, and spatial aspects of

explosive epidemics caused by SARS-CoV-2, Zika virus, chikungunya virus, dengue virus, and

influenza virus, which were the topics of his doctoral dissertation at the University of California,

Berkeley.

**REFERENCES**

1.  McHale T, Romero-Vivas C, Fronterre C, Arango-Padilla P, Waterlow N, Nix C, et al. Spatiotemporal heterogeneity in the distribution of chikungunya and Zika virus case incidences during their 2014 to 2016 epidemics in Barranquilla, Colombia. Int J Environ Res Public Health. 2019 May 2;16(10).

2.  Aguiar BS, Lorenz C, Virginio F, Suesdek L, Chiaravalloti-Neto F. Potential risks of Zika and chikungunya outbreaks in Brazil: A modeling study. Int J Infect Dis. 2018 May 1;70:20–9.

3.  Campos de Lima EE, Gayawan E, Baptista EA, Queiroz BL. Spatial pattern of COVID-19 deaths and infections in small areas of Brazil. PLoS One. 2021 Feb 1;16(2 Febuary).

4.  Vissoci JRN, Rocha TAH, Silva NC da, de Sousa Queiroz RC, Thomaz EBAF, Amaral PVM, et al. Zika virus infection and microcephaly: Evidence regarding geospatial associations. PLoS Negl Trop Dis. 2018 Apr 25;12(4).

5.  Bonilla-Aldana DK, Bonilla-Aldana JL, García-Bustos JJ, Lozada CO, Rodríguez-Morales AJ. Geographical trends of chikungunya and Zika in the Colombian Amazonian gateway department, Caqueta, 2015–2018 – Implications for public health and travel medicine. Travel Med Infect Dis 2020 May 1;35.

6.  Bustos Carrillo F, Collado D, Sanchez N, Ojeda S, Lopez Mercado B, Burger-Calderon R, et al. Epidemiological evidence for lineage-specific differences in the risk of inapparent chikungunya virus infection. J Virol. 2019 Nov 21;93(4):e01622-18.

7.  Gordon A, Gresh L, Ojeda S, Chowell-Puente G, Gonzalez K, Sanchez N, et al. Differences in transmission and disease severity between two successive waves of

chikungunya. Clin Infect Dis. 2018 Apr 25;67(11):1760–7.

8.   Burger-Calderon R, Bustos Carrillo F, Gresh L, Ojeda S, Sanchez N, Plazaola M, et al.

Age-dependent manifestations and case definitions of paediatric Zika: a prospective

cohort study. Lancet Infect Dis. 2020 Dec;20(3):371–80.

9.   Zambrana JV, Bustos Carrillo F, Burger-Calderon R, Collado D, Sanchez N, Ojeda S, et

al. Seroprevalence, risk factor, and spatial analyses of Zika virus infection after the 2016

epidemic in Managua, Nicaragua. Proc Natl Acad Sci. 2018 Sep 11;115(37):9294–9.

10.  Maier HE, Kuan G, Saborio S, Carrillo Bustos F, Plazaola M, Barilla C, et al. Clinical

Spectrum of Severe Acute Respiratory Syndrome Coronavirus 2 Infection and Protection

From Symptomatic Reinfection. Clin Infect Dis. 2021 Aug 19.

11.  Higgs S, Vanlandingham D, Powers A, editors. Chikungunya and Zika Viruses: Global

Emerging Health Threats. 1st ed. Academic Press; 2018.

12.  Cevik M, Kuppalli K, Kindrachuk J, Peiris M. Virology, transmission, and pathogenesis

of SARS-CoV-2. BMJ. 2020 Oct 23;371.

13.  Kuan G, Gordon A, Aviles W, Ortega O, Hammond SN, Elizondo D, et al. The

Nicaraguan Pediatric Dengue Cohort Study: Study design, methods, use of information

technology, and extension to other infectious diseases. Am J Epidemiol. 2009 Jul

1;170(1):120–9.

14.  Saborío Galo S, González K, Téllez Y, García N, Pérez L, Gresh L, et al. Development of

in-house serological methods for diagnosis and surveillance of chikungunya. Rev Panam

Salud Publica. 2017 Aug 21;41:e56.

15.  Balmaseda A, Stettler K, Medialdea-Carrera R, Collado D, Jin X, Zambrana JV, et al.

Antibody-based assay discriminates Zika virus infection from other flaviviruses. Proc Natl

Acad Sci 2017 Aug 1;114(31):8384–9.

16.   Amanat F, Stadlbauer D, Strohmeier S, Nguyen THO, Chromikova V, McMahon M, et al.

A serological assay to detect SARS-CoV-2 seroconversion in humans. Nat Med. 2020 Jul

1;26(7):1033–6.

17.   Hastie T, Tibshirani R. Generalized Additive Models. New York: Chapman & Hall; 1990.

18.   Kulldorff M. A spatial scan statistic. Commun Stat - Theory Methods. 1997;26(6):1481–

96.

19.   Han J, Zhu L, Kulldorff M, Hostovich S, Stinchcomb DG, Tatalovich Z, et al. Using Gini

coefficient to determining optimal cluster reporting sizes for spatial scan statistics. Int J

Health Geogr. 2016 Aug 3;15(1):27.

20.   Rousset F, Ferdy J-B. Testing environmental and genetic effects in the presence of spatial

autocorrelation. Ecography (Cop). 2014;37(8):781–90.

21.   Moore SM, ten Bosch QA, Siraj AS, Soda KJ, España G, Campo A, et al. Local and

regional dynamics of chikungunya virus transmission in Colombia: The role of

mismatched spatial heterogeneity. BMC Med 2018 Aug 30;16(1):152.

22.   Haby M, Pinart M, Elias V, Reveiz L. Prevalence of asymptomatic Zika virus infection: a

systematic review. Bull World Health Organ. 2018 Jun 1;96(6):402-413D.

23.   Sun H, Binder RA, Dickens B, de Sessions PF, Rabaa MA, Ho EXP, et al. Viral genome-

based Zika virus transmission dynamics in a paediatric cohort during the 2016 Nicaragua

epidemic. EBioMedicine. 2021 Oct 1;72.

24.   Hozé N, Paireau J, Lapidus N, Kiem CT, Salje H, Severi G, et al. Monitoring the

proportion of the population infected by SARS-CoV-2 using age-stratified hospitalisation

and serological data: a modelling study. Lancet Public Heal. 2021 Jun 1;6(6):e408–15.

25.   Gordon A, Gresh L, Ojeda S, Katzelnick LC, Sanchez N, Mercado JC, et al. Prior dengue

virus infection and risk of Zika: A pediatric cohort in Nicaragua. von Seidlein L, editor.

PLOS Med. 2019 Jan 22;16(1):e1002726.

   **TABLES**

447   **Table 1.** Summary and descriptive statistics of infection and disease outcomes across four

448   epidemics in the PDCS and HICS in Managua, Nicaragua[*]

| | First chikungunya epidemic (ChikE1) | Second chikungunya epidemic (ChikE2) | Zika epidemic (ZikaE) | COVID-19 epidemic (CovidE) |
|---|---|---|---|---|
| **Cohort** | PDCS | PDCS | PDCS | HICS |
| **Participant age range** | 2-14 | 2-14 | 2-14 | 0-87 |
| **Epidemic period** | 9/2014 – 2/2015 | 7/2015 – 2/2016 | 1/2016 – 1/2017 | 3/2020 – 10/2020 |
| **Primary transmission pathway** | *Aedes* mosquitoes | *Aedes* mosquitoes | *Aedes* mosquitoes | Respiratory droplets |
| **Number at risk of infection** | 3,124 | 2,864 | 3,017 | 1,793 |
| **Number of infections (Number at risk of being a case)** | 199 | 710 | 1,416 | 1,039 |
| **Number of cases** | 90 | 416 | 494 | 306 |
| **Risk of infection (95% CI)[†]** | 6.4% (5.5%, 7.4%) | 24.8% (23.2%, 26.6%) | 47.1% (45.1%, 49.1%) | 57.5% (54.1%, 60.9%) |
| **Risk of disease (95% CI)[†]** | 45.6% (38.6%, 52.6%) | 58.7% (54.9%, 62.4%) | 35.4% (32.8%, 38.1%) | 28.9% (25.5%, 32.5%) |
| **Incidence rate (95% CI)[†]** | 2.9% (2.3%, 3.6%) | 14.5% (13.2%, 16.0%) | 16.6% (15.2%, 18.1%) | 17.1% (14.8%, 19.6%) |
| **Bias due to treating the incidence rate as the infection risk (%)‡** | 2.9% – 6.4% = –3.5% | 14.5% – 24.8% = –10.3% | 16.6% – 47.1% = –30.5% | 17.1% – 57.5% = –40.4% |
| **Bias due to treating the incidence rate as the disease risk (%)‡** | 2.9% – 45.6% = –42.7% | 14.5% – 58.7% = –44.2% | 16.6% – 35.4% = –18.8% | 17.1% – 28.9% = –11.8% |

| ANOVA-based ICC for intra-household correlation of infection risk (95% CI)[§] | 0.22 (0.17, 0.28) | 0.21 (0.16, 0.27) | 0.22 (0.17, 0.27) | 0.30 (0.25, 0.35) |
| --- | --- | --- | --- | --- |
| ANOVA-based ICC for intra-household correlation of disease risk (95% CI)[§] | 0.14 (0.00, 0.51) | 0.26 (0.09, 0.42) | 0.28 (0.18, 0.37) | 0.21 (0.15, 0.28) |

[*]Abbreviations: ANOVA, analysis of variable; CI, confidence interval; GEE, generalized

estimating equations; HICS, Household Influenza Cohort Study; ICC, intracluster correlation

coefficient; PDCS, Pediatric Dengue Cohort Study

[†]GEE model estimates are presented.

[‡]Negative values indicate that the incidence rate underestimates the risk of infection and the risk

of disease.

[§]Table S5 contains additional information.

**Table 2.** Sample size, infection, disease, incidence, and bias metrics from a serosurvey

augmented by cases identifiable by either active or passive surveillance for the 2016 Zika

epidemic in the Pediatric Dengue Cohort Study[*,†]

| | Study design: Serosurvey and active case surveillance[‡] | Study design: Serosurvey and passive case surveillance[§] | Bias due to incomplete case ascertainment[¶] |
|---|---|---|---|
| **Number at risk of infection** | 3,017 | 3,017 | |
| **Number of total infections (Number at risk of being a case)** | 1,416 | 1,416 | |
| **Number of cases (symptomatic infections)** | 494 | 133 | |
| **Number of subclinical infections** | 992 | 1,283 | |
| **Risk of infection (95% CI)[#]** | 47.1% (45.1%, 49.1%) | 47.1% (45.1%, 49.1%) | 47.1% − 47.1% = 0.0%[**] |
| **Risk of disease (95% CI)[#]** | 35.4% (32.8%, 38.1%) | 9.3% (8.0%, 11.0%) | 9.3% − 35.4% = −26.1% |
| **Incidence rate (95% CI)[#]** | 16.6% (15.2%, 18.1%) | 4.4%[††] (3.7%, 5.2%) | 4.4% − 16.6% = −12.2% |
| **Bias due to treating the incidence rate as the infection risk (%)[¶]** | 16.6% − 47.1% = −30.5% | 4.4% − 47.1% = −42.7% | −42.7% + 0.0% = −42.7%[‡‡] (= 4.4% − 47.1%) |
| **Bias due to treating the incidence rate as the disease risk (%)[¶]** | 16.6% − 35.4% = −18.8% | 4.4% − 9.3% = −4.9% | −4.9% + −26.1% = −31.0%[§§] (= 4.4% − 35.4%) |

[*]Abbreviations: CI, confidence interval; GEE, generalized estimating equations; RT-PCR,

reverse transcription polymerase chain reaction

[†]Data in the bottom portion of this table represent the non-spatial version of Figure 6.

‡The first column is the full data for the Zika epidemic obtained by a serosurvey (to capture all

infections) and active case surveillance (to capture all cases). Our active surveillance approach

captured Zika cases with clinical profiles outside of standard Zika case definitions (8) and

augmented RT-PCR with a serological algorithm built from five separate serological assay

results (25). See the Appendix for more details.

§The second column includes the data collected by the serosurvey and Zika cases obtainable

under passive surveillance (*e.g.*, using only standard Zika case definitions and RT-PCR). If a

serosurvey had not been conducted, only the sample size (3,017) and the number of cases (133)

would be known.

¶Negative values indicate that the incidence rate underestimates the risk of infection and the risk

of disease, whether under active or passive case surveillance.

#GEE model estimates are presented.

**Results from a population-level serosurvey would not be impacted by active versus passive

case surveillance at a health facility, so the risk of infection is the same under either active or

passive case surveillance.

††Using passive case surveillance, as is standard, would result in this estimate of the incidence

rate. This is the only metric estimable in the absence of a serosurvey.

‡‡The total bias due to treating the incidence rate, obtained using passively collected case data, as

the true infection risk can be indirectly estimated by summing its constituent biases: the bias of

treating the passive incidence rate as the passive infection risk (–42.7%) and the bias in the

infection risk induced by incomplete case ascertainment (0.0%). A direct estimation of this

compounded bias can also be achieved by subtracting the true infection risk (47.1%) from the

incidence rate based on passive surveillance data (4.4%). Without a serosurvey, it would not be

possible to estimate the true infection risk and hence quantify the degree of bias. However, the

lack of a serosurvey does not remove an existing bias. Thus, even without a serosurvey, –42.7%

is the total bias that would result from inferring the true infection risk from an incidence rate

based on passively collected case data.

§§The total bias due to treating the incidence rate, obtained using passively collected case data, as

the true disease risk can be indirectly estimated by summing its constituent biases: the bias of

treating the passive incidence rate as the passive disease risk (–4.9%) and the bias in the disease

risk induced by incomplete case ascertainment (–26.1%). A direct estimation of this compounded

bias can also be achieved by subtracting the true infection risk (35.4%) from the incidence rate

based on passive surveillance data (4.4%). Without a serosurvey and active case surveillance, it

would not be possible to estimate the true disease risk and hence quantify the degree of bias.

However, the lack of a serosurvey does not remove an existing bias. Thus, even without a

serosurvey, –31.0% is the total bias that would result from inferring the true disease risk from an

incidence rate based on passively collected case data.

 **FIGURE LEGENDS**

**Figure 1. The neighborhoods of the study area in Managua, Nicaragua.** The cemetery is

shown in blue, and the study health center is indicated by a white triangle.

**Figure 2. Epidemic curves for four epidemics in Managua, Nicaragua, on a weekly basis**.

Data for epidemics in the PDCS (A) and HICS (B) are shown. The duration of the annual

sampling periods for serosurveillance of infection history is shown in green. The additional 2020

midyear sampling, instituted to capture the first COVID-19 wave, is shown in orange. The

epidemic curves for the chikungunya and Zika epidemics reflect case counts that were confirmed

by rRT-PCR and a serological algorithm, as detailed in the Appendix. Due to the retrospective

collection of illness onset data from some HICS participants, the COVID-19 epidemic curve

reflects 1) the date of acute sample collection from rRT-PCR-positive cases, 2) the date of illness

onset as reported by ELISA-positive participants, or 3) a randomly selected date from the month

in which ELISA-positive participants recalled experiencing illness consistent with COVID-19.

The epidemic curves for the PDCS and HICS are purposefully shown in different panels as direct

comparisons of case counts between cohorts of different sample sizes can result in misleading

inferences.

**Figure 3. Maps of the infection risk, disease risk, case-based incidence rate, and bias.** The

infection risk (A-D), disease risk (E-H), and incidence rate (I-L) across four epidemics are shown

in one color palette, with warmer colors indicating higher values of the appropriate metric, and

are set against a white background. The difference between infection risk and the incidence rate

(bias induced by treating the incidence rate as the infection risk) (M-P) and the corresponding

bias for the disease risk (Q-T) are shown in another color palette. Bias panels, as they have a

different scale, are set against a gray background. Contour lines show changes in infection,

disease, and bias metrics corresponding to the scale bar of percentages to the right of each plot.

Maps were generated from generalized additive mixed models. A white triangle indicates the

study health center. Neighborhoods are outlined in gray. Columns in the figure correspond to the

chikungunya epidemics (2014, 2015), Zika epidemic (2016), and COVID-19 epidemic (2020) in

Managua, Nicaragua (left to right).

**Figure 4. Cluster detection analyses of the infection risk, disease risk, and case-based**

**incidence rate.** Clusters of infection risk (A-D), disease risk (E-H), and the incidence rate (I-L)

across four epidemics are shown. Panels depict the results of Kulldorf's spatial scan statistic

conducted in SaTScan. Hierarchical clusters are shown in dark colors; Gini clusters are shown in

light colors. Hierarchical clusters identify the most statistically likely clusters; Gini clusters

maximize outcome rates. Hotspots are shown in pink; coldspots are shown in blue.  Cluster

centers are numerically labeled. Arrows show the kind of risk clusters that incidence clusters

resemble. A white triangle indicates the study health center. Neighborhoods are outlined in gray.

Columns in the figure correspond to the chikungunya epidemics (2014, 2015), Zika epidemic

(2016), and COVID-19 epidemic (2020) in Managua, Nicaragua (left to right). Table S2 contains

additional information for this analysis.

**Figure 5. Spatiotemporal dynamics across four epidemics in our study area.** Model

predictions of the infection risk (A-D, first column) and incidence rate (E-H, second column) are

reported per-month and per-1,000 population. Due to space constraints, data for months with few

cases are not shown. The PDCS epidemics (ChikE1, ChikE2, and ZikaE) are shown in a different

color palette than CovidE as the range of the infection dynamics for CovidE is so much higher

than that of the PDCS epidemics. Contour lines show changes in infection and incidence metrics

corresponding to the scale bar of percentages to the right of each plot. A white triangle indicates

the study health center. Neighborhoods are outlined in gray. Rows in the figure correspond to the

chikungunya epidemics (2014, 2015), Zika epidemic (2016), and COVID-19 epidemic (2020) in

Managua, Nicaragua (top to bottom).

**Figure 6. Comparisons of infection, disease, incidence, and bias metrics for the 2016 Zika**

**epidemic in the PDCS using passive and active case surveillance.** Panels in this figure are

displayed in the same sequence as, and represent the spatial version of, data in the bottom portion

of Table 2. Columns in this figure correspond to a study design using a serosurvey and active

case surveillance (column 1), a study design using a serosurvey and passive case surveillance

(column 2), and the bias induced by passive versus active case surveillance (column 3). Column

1 repeats the data shown in Figure 3, column 3 for the sake of comparing the full data to that

obtained under passive case surveillance. Maps of the infection risk (A, F), disease risk (B, G),

and the incidence rate (C, H) are shown under active and passive case surveillance in the first

color palette and are distinguished by a white map background. The bias induced by active

versus passive case surveillance for these three metrics (K-M) is shown in a second color palette

distinguished by a green map background. The bias induced by treating the incidence rate as the

infection risk (D, I) and the incidence rate as the disease risk (E, J) is shown in a third color

palette distinguished by a grey map background. The total bias incurred from incomplete case

ascertainment and inferring a risk from the incidence rate (N-O) is shown in a fourth color

palette distinguished by a pink map background. Contour lines show changes in infection,

disease, incidence, and bias metrics corresponding to the scale bar of percentages to the right of

each plot. Maps were generated from generalized additive mixed models. A white triangle

indicates the study health center. Neighborhoods are outlined in gray.